Alvotech says FDA closes Reykjavik plant inspection with VAI classification

The FDA has concluded its May 2026 inspection of Alvotech’s Reykjavik manufacturing facility with a Voluntary Action Indicated (VAI) classification. This outcome reduces regulatory uncertainty regarding the plant's compliance status, supporting Alvotech's efforts to advance recent biosimilar Biologics License Application (BLA) filings toward approval.

FDA closed its May 2026 inspection of Alvotech’s Reykjavik manufacturing site with a Voluntary Action Indicated (VAI) classification. * The outcome reduces regulatory overhang on the plant’s compliance status as Alvotech works to move recent biosimilar BLA filings toward approval. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607290925PRIMZONEFULLFEED1001255006) on July 29, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)